Chief Scientific Officer Dr. Chris Twitty highlighted the significance of nimacimab’s differentiated mechanism, which may maintain efficacy even when the CB1 receptor and its natural ligands are ...

Nimacimab is a humanized IgG4 negative allosteric modulating antibody that specifically binds to the CB1 receptor with no cross-reactivity to other G-protein-coupled receptors, including ...

“This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor—nimacimab—effectively drives weight loss in a DIO model. Nimacimab compared favorably to and ...

The move for Embark Biotech comes shortly after Novo Nordisk agreed to acquire Inversago and its peripherally acting CB1 receptor (CB1r) blocker therapies for up to $1.075 billion. The lead ...

Dr. Chris Twitty, Chief Scientific Officer of Skye, said, “These data demonstrate for the first time how nimacimab’s allosteric binding to the CB1 receptor is differentiated from the small molecules ...

Chief Scientific Officer Dr. Chris Twitty highlighted the significance of nimacimab’s differentiated mechanism, which may maintain efficacy even when the CB1 receptor and its natural ligands are ...

Within the ECS, we have two main types of cannabinoid receptors: CB1 Receptors: Primarily found in the brain and central nervous system. These guys are heavily involved in things like mood, memory, ...

What do you know about the effects of extreme weather events on human health? Test your knowledge with this quick quiz.

Deepak D'Souza, the Vikram Sodhi ’92 Professor of Psychiatry at Yale, explains risks from highly potent cannabinoids and research on treating mental health conditions with psychedelics. Harlan reports ...